Navigation Links
Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
Date:2/23/2011

HORSHAM, Pa., Feb. 23, 2011 /PRNewswire/ -- Centocor Ortho Biotech Inc. (Centocor) today received a decision from the Court of Appeals for the Federal Circuit in Washington, D.C. overturning a 2009 federal court jury verdict that awarded the company $1.8 billion after finding Abbott Laboratories liable for patent infringement.

A panel of the court ruled that the patent relating to Centocor anti-tumor necrosis factor (TNF) -alpha rheumatoid arthritis treatments was invalid.

"We are disappointed by the decision," said Rob Bazemore, president of Centocor Ortho Biotech Inc.  "We are considering whether to ask for reconsideration by the panel or by the court of appeals as a whole."

The original verdict was returned in June 2009 by a U.S. District Court jury in Marshall, Texas.  The patent is co-owned by New York University and Centocor, the exclusive licensee.

About Centocor Ortho Biotech Inc.

Centocor Ortho Biotech Inc. redefines the standard of care in immunology, nephrology, and oncology. Built upon a pioneering history, Centocor Ortho Biotech Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care. For more information about Centocor Ortho Biotech, visit www.CentocorOrthoBiotech.com.  Centocor Ortho Biotech Inc. is a wholly owned subsidiary of Johnson & Johnson (NYSE: JNJ).

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Centocor Ortho Biotech Inc. and/or Johnson & Johnson. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Centocor Ortho Biotech Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.


'/>"/>
SOURCE Centocor Ortho Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
3. Pharma CI Conference Amy Yueh Pays $52,000 to Apaporis LLC to Satisfy Judgment Against Her In Superior Court Of New Jersey Case
4. Montana Supreme Court Decision Endangers Most Vulnerable Citizens
5. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
6. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
7. CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures
8. Texas Court Asked to Appoint Receiver for Key Subsidiary of TSX Listed Northstar Healthcare, Inc. (TSX NHC) on Claims of Mismanagement and Breach of Fiduciary Duty
9. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
10. Appellate Court Decides in Favor of Fenwal
11. CRESTOR® Patent Upheld By US Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/4/2017)... , Aug. 4, 2017 The search ... shortly after a physician/patient consult has long been the ... was a notable focus of the largest meeting of ... according to healthcare market research firm Kalorama Information.  The ... testing (POCT) offerings or related supplies and software were ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... uses UVC light energy to kill deadly pathogens such as C. diff , MRSA, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology:
(Date:8/21/2017)... CA (PRWEB) , ... August 21, 2017 , ... ... health services business of UnitedHealth Group (NYSE: UNH), has made a multi-million dollar ... responders affected by post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI) over ...
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult with gluten intolerance ... you may be interested in participating in a research study that focuses on family ... understand more about the relational aspects of adults who have gluten sensitivities who cohabitate ...
(Date:8/19/2017)... ... August 19, 2017 , ... The digital health and ... with pending recognition status from the Centers for Disease Control and Prevention (“CDC”) ... and live video conferencing. , The DPP resulted from clinical work conducted ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of America ... as an interventional pain management physician. He brings a wealth of pain management ... headaches, and significant experience in spinal cord stimulation for chronic pain. , Dr. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... a highly specialized asset-light logistics provider of complex transport solutions for mission-critical ... to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. ...
Breaking Medicine News(10 mins):